What is the Study?
This study tests an investigational drug called solanezumab in older adults who are at risk for future memory loss.
What is the Purpose of A4 Study?
Scientists believe that Alzheimer's disease-related damage to the brain begins many years before the symptoms of memory loss emerge. It is hoped that starting treatment very early will help slow the onset and progression of memory loss.
The study lasts about three years and three months and will involve monthly infusions of the study drug, as well as occasional memory tests, brain scans, and blood draws. This treatment is free of charge. You will be compensated for your time.
Read more about the importance of the A4 trial.
Participants must be ages 65-85 fairly healthy adults with normal memory and thinking abilities. Participants who are enrolled into the treatment portion of the study will have markers on a brain scan that suggest Alzheimer's disease may develop in the future. It is not required that you have a family history of Alzheimer's disease to participate.
If you are interested in learning more about the A4 Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease, please call (401) 455-6403 or send an e-mail to: firstname.lastname@example.org. Ask about the "A4 Study."
For information on other current research studies at Butler Hospital please click here.